Skip to main content

Advertisement

Table 1 Characteristics of participants by study area

From: Resisting and tolerating P. falciparum in pregnancy under different malaria transmission intensities

  HIV-uninfecteda HIV-infectedb
All Benin Gabon Mozambique All Kenya Mozambique
n = 946 n = 349 n = 257 n = 340 n = 768 n = 351 n = 417
Age (years), mean (SD)
  24.3 (6.3) 25.4 (5.2) 24.4 (6.7) 23.1 (6.8) 26.7 (5.7) 26.9 (5.4) 26.5 (5.9)
Parity, n (%)
 Primigravidae 265 (28) 69 (20) 66 (26) 130 (38) 81 (11) 30 (9) 51 (12)
 Multigravidae 681 (72) 280 (80) 191 (74) 210 (62) 687 (89) 321 (91) 366 (88)
Gestational age at baseline (weeks), mean (SD)
  21.0 (4.9) 22.0 (4.1) 19.5 (5.4) 21.3 (5.2) 20.3 (5.5) 19.9 (5.9) 20.6 (5.2)
MUAC at baseline (cm), mean (SD)
  25.9 (3.0) 25.3 (2.3) 25.7 (3.6) 26.8 (3.0) 26.8 (2.7) 27.0 (2.7) 26.7 (2.7)
RPR at baseline, n (%)
 Positive 9 (1) 2 (1) 1 (0) 6 (2) 39 (5) 12 (3) 27 (7)
 Negative 928 (99) 347 (99) 247 (100) 334 (98) 726 (95) 338 (97) 388 (93)
Literate, n (%)
 No 371 (39) 280 (80) 34 (13) 57 (17) 142 (18) 16 (5) 126 (30)
 Yes 575 (61) 69 (20) 223 (87) 283 (83) 626 (82) 335 (95) 291 (70)
HIV viral load (copies/mL) at baseline, n (%)c
  < 399      181 (24) 125 (36) 56 (13)
 400/999      183 (24) 76 (22) 107 (26)
 1000/9999      243 (32) 97 (28 146 (35)
 10,000/max      123 (16) 49 (14) 74 (18)
 UNK      38 (5) 4 (1) 34 (8)
CD4 (cells/μL) at baseline, n (%)d
  < 350      279 (36) 137 (39) 142 (34)
 350/max      460 (60) 212 (60) 248 (59)
 UNK      29 (4) 2 (1) 27 (6)
Maternal haemoglobin at baseline (g/dL), mean (SD)
  10.4 (1.5) 10.3 (1.2) 10.3 (1.4) 10.7 (1.8) 10.1 (1.7) 10.2 (1.9) 10.0 (1.6)
IPTp, n (%)
 Antimalarial 1e 629 (66) 230 (66) 172 (67) 227 (67) 390 (51) 174 (50) 216 (52)
 Antimalarial 2e 317 (34) 119 (34) 85 (33) 113 (33) 378 (49) 177 (50) 201 (48))
Gestational age at delivery (weeks),f mean (SD)
  39.6 (1.7) 39.2 (1.2) 41.1 (1.8) 38.9 (1.2) 38.8 (1.2) ND 38.8 (1.2)
Preterm birth,g n (%)
 No 867 (95) 328 (95) 238 (95) 301 (95) 374 (96) ND 374 (96)
 Yes 44 (5) 16 (5) 13 (5) 15 (5) 17 (4) ND 17 (4)
  1. aThe IPTp trial evaluated the efficacy and safety of two doses of Intermittent Preventive Treatment in pregnancy (IPTp) with mefloquine compared to IPTp with sulphadoxine-pyrimethamine
  2. bEvaluated three doses of IPTp with MQ compared to placebo in HIV-infected women on cotrimoxazole prophylaxis
  3. c38 missing values
  4. d29 missing values
  5. eAntimalarial: 1 = Mefloquine and 2 = Sulphadoxine-Pyrimethamine for HIV-uninfected; 1 = Placebo and 2 = Mefloquine for HIV-infected
  6. fGestational age was estimated by newborn physical examination using the Ballard score
  7. gPreterm birth if gestational age was < 37 weeks
  8. IPTp intermittent preventive treatment, MUAC mid-upper arm circumference, RPR rapid plasma reagin, UNK unknown